Catalyst Pharma (CN2) Stock Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CN2 Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Catalyst

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CN2 Stock 12 Month Forecast

Average Price Target

€29.39

▲(60.41% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is €29.39 with a high forecast of €30.25 and a low forecast of €28.52. The average price target represents a 60.41% change from the last price of €18.32.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","31":"€31","19.75":"€19.75","23.5":"€23.5","27.25":"€27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.25226925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.3879187,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€29.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.52356815,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€28.52</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,19.75,23.5,27.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.73,18.69325148076923,19.65650296153846,20.619754442307695,21.583005923076925,22.546257403846155,23.509508884615386,24.472760365384616,25.436011846153846,26.399263326923077,27.362514807692307,28.325766288461537,29.28901776923077,{"y":30.25226925,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.73,18.62676297692308,19.523525953846153,20.42028893076923,21.31705190769231,22.213814884615385,23.110577861538463,24.007340838461538,24.904103815384616,25.800866792307694,26.69762976923077,27.594392746153847,28.491155723076922,{"y":29.3879187,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.73,18.560274473076923,19.390548946153846,20.22082341923077,21.05109789230769,21.881372365384614,22.71164683846154,23.54192131153846,24.372195784615386,25.202470257692305,26.03274473076923,26.86301920384615,27.693293676923076,{"y":28.52356815,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.565,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.33,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.51,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.335,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.705,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.615,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€30.25

Average Price Target€29.39

Lowest Price Target€28.52

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leland Gershell

Oppenheimer

€27.76→€28.63

Buy

56.27%

Upside

Reiterated

11/07/25

Catalyst Pharmaceuticals price target raised to $33 from $32 at OppenheimerCatalyst Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

Jason Gerberry

Bank of America Securities

€29.5→€30.36

Buy

65.74%

Upside

Reiterated

11/06/25

Bank of America Securities Sticks to Their Buy Rating for Catalyst Pharma (CPRX)

Samantha Semenkow

Citi

€26.89→€28.63

Buy

56.27%

Upside

Reiterated

11/06/25

Catalyst Pharmaceuticals price target raised to $33 from $31 at CitiCatalyst Pharmaceuticals price target raised to $33 from $31 at Citi

Andrew Fein

H.C. Wainwright

€30.36

Buy

65.74%

Upside

Reiterated

09/17/25

Catalyst Pharma (CPRX) Gets a Buy from H.C. Wainwright

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/07/25

Truist Financial Reaffirms Their Buy Rating on Catalyst Pharma (CPRX)

Joel Beatty

Robert W. Baird

€24.29→€27.76

Buy

51.54%

Upside

Reiterated

03/03/25

Catalyst Pharmaceuticals price target raised to $32 from $28 at BairdCatalyst Pharmaceuticals price target raised to $32 from $28 at Baird

Sudan Loganathan

Stephens

€28.63→€34.7

Buy

89.42%

Upside

Reiterated

02/28/25

Catalyst Pharmaceuticals price target raised to $40 from $33 at StephensCatalyst Pharmaceuticals price target raised to $40 from $33 at Stephens

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leland Gershell

Oppenheimer

€27.76→€28.63

Buy

56.27%

Upside

Reiterated

11/07/25

Catalyst Pharmaceuticals price target raised to $33 from $32 at OppenheimerCatalyst Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

Jason Gerberry

Bank of America Securities

€29.5→€30.36

Buy

65.74%

Upside

Reiterated

11/06/25

Bank of America Securities Sticks to Their Buy Rating for Catalyst Pharma (CPRX)

Samantha Semenkow

Citi

€26.89→€28.63

Buy

56.27%

Upside

Reiterated

11/06/25

Catalyst Pharmaceuticals price target raised to $33 from $31 at CitiCatalyst Pharmaceuticals price target raised to $33 from $31 at Citi

Andrew Fein

H.C. Wainwright

€30.36

Buy

65.74%

Upside

Reiterated

09/17/25

Catalyst Pharma (CPRX) Gets a Buy from H.C. Wainwright

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/07/25

Truist Financial Reaffirms Their Buy Rating on Catalyst Pharma (CPRX)

Joel Beatty

Robert W. Baird

€24.29→€27.76

Buy

51.54%

Upside

Reiterated

03/03/25

Catalyst Pharmaceuticals price target raised to $32 from $28 at BairdCatalyst Pharmaceuticals price target raised to $32 from $28 at Baird

Sudan Loganathan

Stephens

€28.63→€34.7

Buy

89.42%

Upside

Reiterated

02/28/25

Catalyst Pharmaceuticals price target raised to $40 from $33 at StephensCatalyst Pharmaceuticals price target raised to $40 from $33 at Stephens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Catalyst Pharma

1 Month

xxx

Success Rate

8/12 ratings generated profit

Average Return

+5.16%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.16% per trade.

3 Months

xxx

Success Rate

18/27 ratings generated profit

Average Return

+7.05%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +7.05% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

10/14 ratings generated profit

Average Return

+19.10%

reiterated a buy rating 2 days ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +19.10% per trade.

2 Years

xxx

Success Rate

22/27 ratings generated profit

Average Return

+67.57%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 81.48% of your transactions generating a profit, with an average return of +67.57% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CN2 Analyst Recommendation Trends

Rating

Jun 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CN2 has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CN2 average Analyst price target in the past 3 months is 29.39.

Each month's total comprises the sum of three months' worth of ratings.

CN2 Financial Forecast

CN2 Earnings Forecast

Next quarter’s earnings estimate for CN2 is €0.26 with a range of €0.18 to €0.30. The previous quarter’s EPS was €0.36. CN2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year CN2 has Preformed in-line its overall industry.

CN2 Sales Forecast

Next quarter’s sales forecast for CN2 is €121.84M with a range of €116.77M to €129.34M. The previous quarter’s sales results were €128.26M. CN2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year CN2 has Preformed in-line its overall industry.

CN2 Stock Forecast FAQ

What is DE:CN2’s average 12-month price target, according to analysts?

Based on analyst ratings, Catalyst Pharmaceutical Partners’s 12-month average price target is 29.39.

What is DE:CN2’s upside potential, based on the analysts’ average price target?

Catalyst Pharmaceutical Partners has 60.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Catalyst Pharmaceutical Partners a Buy, Sell or Hold?

Catalyst Pharmaceutical Partners has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Catalyst Pharmaceutical Partners’s share price target?

The average share price target for Catalyst Pharmaceutical Partners is 29.39. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €30.25 ,and the lowest forecast is €28.52. The average share price target represents 60.41% Increase from the current price of €18.32.

What do analysts say about Catalyst Pharmaceutical Partners?

Catalyst Pharmaceutical Partners’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Catalyst Pharmaceutical Partners?

To buy shares of DE:CN2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Catalyst Pharma (CN2) Stock Forecast & Price Target

CN2 Analyst Ratings

CN2 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Catalyst Pharma

CN2 Analyst Recommendation Trends

CN2 Financial Forecast

CN2 Earnings Forecast

CN2 Sales Forecast

CN2 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts